Therapeutic targets and biomarkers of tumor immunotherapy:response versus non-response  

作　　者：Dong-Rui Wang Xian-Lin Wu Ying-Li Sun 

机构地区：[1]Bone Marrow Transplantation Center,The First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou,China [2]Liangzhu Laboratory,Zhejiang University Medical Center,Hangzhou,China [3]Institute of Hematology,Zhejiang University,Hangzhou,China [4]Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy,Hangzhou,China [5]Central Laboratory,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen Hospital,Chinese Academic of Medical Sciences and Peking Union Medical College,Shenzhen,China [6]CAS Key Laboratory of Genomic Precision Medicine,Beijing Institute of Genomics,Chinese Academy of Sciences,Beijing,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第10期3784-3810,共27页信号转导与靶向治疗（英文）

基　　金：supported by the National Key R&D Program of China(2019YFC1315701 to Y.S.);sponsored by National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen Hospital,Chinese Academic of Medical Sciences and Peking Union Medical College,Shenzhen(SZ2020ZD004,E010121002);supported by Sanming Project of Medicine in Shenzhen(No.SZSM201812062,No.SZSM201612097);Shenzhen Science and Technology Program(KCXFZ20201221173008022);Shenzhen Key Medical Discipline Construction Fund(No.SZXK075).

摘　　要：Cancers are highly complex diseases that are characterized by not only the overgrowth of malignant cells but also an altered immune response.The inhibition and reprogramming of the immune system play critical roles in tumor initiation and progression.Immunotherapy aims to reactivate antitumor immune cells and overcome the immune escape mechanisms of tumors.Represented by immune checkpoint blockade and adoptive cell transfer,tumor immunotherapy has seen tremendous success in the clinic,with the capability to induce long-term regression of some tumors that are refractory to all other treatments.Among them,immune checkpoint blocking therapy,represented by PD-1/PD-L1 inhibitors(nivolumab)and CTLA-4 inhibitors(ipilimumab),has shown encouraging therapeutic effects in the treatment of various malignant tumors,such as non-small cell lung cancer(NSCLC)and melanoma.In addition,with the advent of CAR-T,CAR-M and other novel immunotherapy methods,immunotherapy has entered a new era.At present,evidence indicates that the combination of multiple immunotherapy methods may be one way to improve the therapeutic effect.However,the overall clinical response rate of tumor immunotherapy still needs improvement,which warrants the development of novel therapeutic designs as well as the discovery of biomarkers that can guide the prescription of these agents.Learning from the past success and failure of both clinical and basic research is critical for the rational design of studies in the future.In this article,we describe the efforts to manipulate the immune system against cancer and discuss different targets and cell types that can be exploited to promote the antitumor immune response.

关 键 词：IMMUNOTHERAPY PRESCRIPTION OVERCOME 

分 类 号：R730.51[医药卫生—肿瘤]